Literature DB >> 23696564

Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis.

Anat Ben-Shlomo1, Oxana Pichurin, Ramtin Khalafi, Cuiqi Zhou, Vera Chesnokova, Song-Guang Ren, Ning-Ai Liu, Shlomo Melmed.   

Abstract

Somatostatin signals predominantly through somatostatin receptor (SSTR) subtype 2 to attenuate GH release. However, the independent role of the receptor in regulating GH synthesis is unclear. Because we had previously demonstrated constitutive SSTR2 activity in mouse corticotrophs, we now analyzed GH regulation in rat pituitary somatotroph (GC) tumor cells, which express SSTR2 exclusively and are devoid of endogenous somatostatin ligand. We demonstrate that moderately stable SSTR2 overexpression (GpSSTR2(WT) cells) was associated with decreased GH promoter activity, GH mRNA, and hormone levels compared with those of control transfectants (GpCon cells). In contrast, levels of GH mRNA and peptide and GH promoter activity were unchanged in GpSSTR2(DRY) stable transfectants moderately expressing DRY motif mutated SSTR2 (R140A). GpSSTR(2DRY) did not exhibit an enhanced octreotide response as did GpSSTR2(WT) cells; however, both SSTR2(WT)-enhanced yellow fluorescent protein (eYFP) and SSTR2(DRY)-eYFP internalized on octreotide treatment. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, increased GH synthesis in wild-type GC cells and primary pituitary cultures. GpSSTR2(WT) cells induced GH synthesis more strongly on SAHA treatment, evident by both higher GH peptide and mRNA levels compared with the moderate but similar GH increase observed in GpCon and GpSSTR2(DRY) cells. In vivo SAHA also increased GH release from GpSSTR2(WT) but not from control xenografts. Endogenous rat GH promoter chromatin immunoprecipitation showed decreased baseline acetylation of the GH promoter with exacerbated acetylation after SAHA treatment in GpSSTR2(WT) compared with that of either GpSSTR(2DRY) or control cells, the latter 2 transfectants exhibiting similar GH promoter acetylation levels. In conclusion, modestly increased SSTR2 expression constitutively decreases GH synthesis, an effect partially mediated by GH promoter histone deacetylation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23696564      PMCID: PMC3689284          DOI: 10.1210/en.2013-1132

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  39 in total

Review 1.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.

Authors:  Roland Seifert; Katharina Wenzel-Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-06       Impact factor: 3.000

Review 2.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Authors:  Gisbert Weckbecker; Ian Lewis; Rainer Albert; Herbert A Schmid; Daniel Hoyer; Christian Bruns
Journal:  Nat Rev Drug Discov       Date:  2003-12       Impact factor: 84.694

3.  Homologous upregulation of sst2 somatostatin receptor expression in the rat arcuate nucleus in vivo.

Authors:  G S Tannenbaum; J Turner; F Guo; C Videau; J Epelbaum; A Beaudet
Journal:  Neuroendocrinology       Date:  2001-07       Impact factor: 4.914

4.  Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists.

Authors:  D Cervia; P Zizzari; B Pavan; E Schuepbach; D Langenegger; D Hoyer; C Biondi; J Epelbaum; P Bagnoli
Journal:  Neuropharmacology       Date:  2003-04       Impact factor: 5.250

5.  A defined locus control region determinant links chromatin domain acetylation with long-range gene activation.

Authors:  Yugong Ho; Felice Elefant; Nancy Cooke; Stephen Liebhaber
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

6.  Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst(2) but not sst(1) receptors are coupled to inhibition of single-cell intracellular free calcium concentrations.

Authors:  Davide Cervia; Cristina Petrucci; Marie Thérèse Bluet-Pajot; Jacques Epelbaum; Paola Bagnoli
Journal:  Neuroendocrinology       Date:  2002-08       Impact factor: 4.914

Review 7.  Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis.

Authors:  Lawrence A Frohman; Rhonda D Kineman
Journal:  Trends Endocrinol Metab       Date:  2002-09       Impact factor: 12.015

8.  Autoregulation of pituitary growth hormone messenger ribonucleic acid levels in rats bearing transplantable mammosomatotrophic pituitary tumors.

Authors:  S Yamashita; S Slanina; H Kado; S Melmed
Journal:  Endocrinology       Date:  1986-03       Impact factor: 4.736

9.  Independent effects of growth hormone releasing factor on growth hormone release and gene transcription.

Authors:  M Barinaga; L M Bilezikjian; W W Vale; M G Rosenfeld; R M Evans
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

10.  Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophysial cells.

Authors:  J W Tanner; S K Davis; N H McArthur; J T French; T H Welsh
Journal:  J Endocrinol       Date:  1990-04       Impact factor: 4.286

View more
  5 in total

Review 1.  Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Ning-Ai Liu; Shlomo Melmed
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues.

Authors:  Qing Bo; Fan Yang; Yingge Li; Xianyu Meng; Huanhuan Zhang; Yingxin Zhou; Shenglong Ling; Demeng Sun; Pei Lv; Lei Liu; Pan Shi; Changlin Tian
Journal:  Cell Discov       Date:  2022-05-20       Impact factor: 38.079

3.  Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis.

Authors:  Tamar Eigler; Anat Ben-Shlomo; Cuiqi Zhou; Ramtin Khalafi; Song-Guang Ren; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2014-02-25

4.  Leptin Modulates the Response of Brown Adipose Tissue to Negative Energy Balance: Implication of the GH/IGF-I Axis.

Authors:  Vicente Barrios; Laura M Frago; Sandra Canelles; Santiago Guerra-Cantera; Eduardo Arilla-Ferreiro; Julie A Chowen; Jesús Argente
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

5.  Cerebral Insulin Bolus Revokes the Changes in Hepatic Lipid Metabolism Induced by Chronic Central Leptin Infusion.

Authors:  Vicente Barrios; Elena López-Villar; Laura M Frago; Sandra Canelles; Francisca Díaz-González; Emma Burgos-Ramos; Gema Frühbeck; Julie A Chowen; Jesús Argente
Journal:  Cells       Date:  2021-03-06       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.